Chu Grenoble Alpes
Grenoble, 38043, France
NCT Number: NCT03857191
In obese patients, the prevalence of obstructive sleep apnea (OSA) is around 40% in men and 30% in women. Weight loss after bariatric surgery significantly improves OSA, with 75% of patients having a reduction in OSA severity or becoming non-apneic. We hypothesize a similar effect on OSA of nutritional and psychocomportemental rehabilitation for obese patients. However, we expect weight loss and blood pressure reduction to probably be lower in obese patients who have OSA and nutritional rehabilitation alone than in those who are treated for their OSA or are without OSA. To address this question, we will conduct an observational study on obese patients, treated or not for OSA, following nutritional and psychocomportemental rehabilitation.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Grenoble, 38043, France
In obese patients, OSA prevalence is around 40% in men and 30% in women. Being overweight or obese are independent risk factors for OSA, and the prevalence increases with body mass index (BMI). Weight loss after bariatric surgery is one treatment for OSA, 75% of patients having a reduction in OSA severity or becoming non-apneic. OSA and obesity both induce type 2 diabetes, hypertension and/or nonalcoholic fatty liver disease (NAFLD). A randomized study (Chirinos et al. NEJM 2014) demonstrated a better improvement in blood pressure, triglyceride levels or insulin resistance with weight loss alone or weight loss associated with continuous positive airway pressure (CPAP) than with CPAP alone. We hypothesize a similar effect of nutritional and psychocomportemental rehabilitation on OSA. However, weight loss and blood pressure improvements could be lesser in untreated OSA patients than in treated OSA or non-OSA patients. It has been demonstrated that bariatric surgery reduces medication use such as antihypertensive or antidiabetic drugs, and thus a secondary objective is to determine whether nutritional and psychocomportemental rehabilitation similarly reduces medication use by the overweight and obese.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Nutritional psychocomportemental rehabilitation
Time frame: 25 weeks
Berlin questionnaire score of patients will be compared before and after weight loss (if any) by nutritional psychocomportemental reeducation
Time frame: 25 weeks
Epworth sleepiness score of patients will be compared before and after weight loss by nutritional psychocomportemental rehabilitation
Time frame: 25 weeks
Weight loss will be compared according to the somnolence and/or OSA risk defined by Berlin score
Time frame: 25 weeks
Blood pressure reduction between the beginning and the end of the dietary program will be compared according to OSA risk defined by Berlin score
Time frame: 25 weeks
Change in the number of antihypertensive, antidiabetic and lipid lowering drug use will be compared according to the change in Berlin questionnaire score
Time frame: 25 weeks
To determine the percentage of patients stopping CPAP treatment after weight loss
University Hospital, Grenoble
Other
Nutritional and Psychocomportemental Reeducation, Sleep Apnea and Comorbidities in Overweight and Obese Subjects
Acronym: DIETSLEEP
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03133156
Behavior, Body Weight
Boston, Massachusetts, United States
View Trial DetailsNCT06141967
Apnea, Body Weight
Saint-Etienne, France
View Trial DetailsNCT04115657
Body Weight, Diabete Type 2
Singapore
View Trial DetailsNCT02871882
Body Weight, Diabetes Mellitus
Rochester, Minnesota, United States
View Trial Details